TVTX icon

TVTX

Lightning icon

31.11 USD

+1.66%

Today

-0.03%

1D

Last seen at Tue, 24 Feb 2026 23:42:00 GMT+3

Market is closed

Sun

Closed

Mon

4:30 PM ~ 10:59 PM

Tue

4:30 PM ~ 10:59 PM

Wed

4:30 PM ~ 10:59 PM

Thu

4:30 PM ~ 10:59 PM

Fri

4:30 PM ~ 10:59 PM

Sat

Closed

1D
5D
1M
3M
1Y
MAX

Performance

1 Day

- 0.03 %

1 Week

+ 7.56 %

1 Month

+ 4.51 %

3 Month

- 14.46 %

6 Month

+ 77.85 %

1 Year

+ 44.50 %

Information

Name

Travere Therapeutics Inc Leveraged

Currency

USD

Standard Leverage

1X

Lightning Icon

Enhanced Leverage

3X

Lightning Icon

Overnight Fees Buy

-0.0191%

Overnight Fees Sell

0.0024%

Market Cap

3.13B

Avg Daily Volume

1.72M

52 Week High

36.87 USD

52 Week Low

12.91 USD

Trading Hours

See hours

Overnight Fees Calculator

ExposureUnits
USD
Daily Overnight Fee %Daily Overnight Fee $
BUYS-0.01910%$(0.191)
SELLS0.00240%$0.024

*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.

Business Summary

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Top News

Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook

finance.yahoo.com

3mo ago

No Image

AdvanceAutoParts

-2.99%

Dropbox

-0.78%

Target initiated, Nike upgraded: Wall Street's top analyst calls

finance.yahoo.com

5mo ago

No Image

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

finance.yahoo.com

7mo ago

No Image

Show more

Frequently Asked Questions

What are healthcare stocks and why are they important to investors?

Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.


Are healthcare stocks less volatile?

Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.


What drives growth in healthcare investments?

Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.


What are the risks of investing in healthcare?

Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.